Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Next Previous
Trial Profile

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Biodel

    • Most Recent Events

    • 21 Apr 2012 Planned patient number is changed from 222 to 400 as reported by European Clinical Trials Database record (Extension trial; EudraCT2007-006084-73).
    • 21 Apr 2012 Planned patient number is changed from 222 to 400 as reported by European Clinical Trials Database record (Extension trial; EudraCT2007-006084-73).
    • 21 Apr 2012 Investigational drug identified as (Insulin-glargine) as reported by European Clinical Trials Database record (Extension trial; EudraCT2007-006084-73).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top